Neuroone Medical Financials
NMTC Stock | USD 0.76 0.02 2.70% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 0.0086 | 2.0924 |
|
|
The essential information of the day-to-day investment outlook for Neuroone Medical includes many different criteria found on its balance sheet. An individual investor should monitor Neuroone Medical's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Neuroone Medical.
Net Income |
|
Neuroone | Select Account or Indicator |
Please note, the presentation of Neuroone Medical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Neuroone Medical's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Neuroone Medical's management manipulating its earnings.
Neuroone Medical Stock Summary
Neuroone Medical competes with BioSig Technologies,, Biomerica, Beyond Air, Movano, and SANUWAVE Health. NeuroOne Medical Technologies Corporation operates as a medical technology company. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOnes combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. Neuroone Medical operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 11 people.Specialization | Health Care, Health Care Equipment & Services |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US64130M2098 |
CUSIP | 64130M209 64130M100 686211103 |
Location | Minnesota; U.S.A |
Business Address | 7599 Anagram Drive, |
Sector | Health Care Equipment & Supplies |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.n1mtc.com |
Phone | 952 426 1383 |
Currency | USD - US Dollar |
Neuroone Medical Key Financial Ratios
Return On Equity | -3.49 | ||||
Operating Margin | (3.38) % | ||||
Price To Sales | 5.96 X | ||||
Revenue | 3.45 M | ||||
Gross Profit | (3.05 M) |
Neuroone Medical Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 4.8M | 7.9M | 12.8M | 8.1M | 5.4M | 3.0M | |
Other Current Liab | 454.9K | 531.5K | 632.5K | 978.4K | 1.1M | 1.2M | |
Net Debt | (2.7M) | (6.6M) | (8.0M) | (5.1M) | (1.2M) | (1.3M) | |
Retained Earnings | (30.9M) | (40.8M) | (50.8M) | (62.7M) | (75.0M) | (71.3M) | |
Cash | 4.0M | 6.9M | 8.2M | 5.3M | 1.5M | 2.0M | |
Total Liab | 2.7M | 1.4M | 3.2M | 1.8M | 4.5M | 4.8M | |
Total Current Assets | 4.2M | 7.3M | 12.2M | 7.3M | 4.6M | 2.7M | |
Common Stock | 22.2K | 12.0K | 16.2K | 23.9K | 30.8K | 32.4K | |
Accounts Payable | 762.5K | 528.8K | 927.7K | 685.1K | 1.0M | 535.1K | |
Net Tangible Assets | (1.4M) | 1.9M | 6.4M | 9.5M | 10.9M | 11.5M | |
Other Current Assets | 118.6K | 244.0K | 296.6K | 263.7K | 359.1K | 377.0K | |
Intangible Assets | 156.5K | 134.2K | 111.9K | 89.6K | 67.3K | 113.3K | |
Net Invested Capital | 3.1M | 6.6M | 9.6M | 6.2M | 822.0K | 780.9K | |
Net Working Capital | 1.8M | 6.1M | 9.1M | 5.5M | 2.4M | 2.2M | |
Capital Stock | 22.2K | 35.8K | 16.2K | 23.9K | 30.8K | 23.9K |
Neuroone Medical Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 284.6K | 7.5M | 3.1K | 31.2K | 229.0K | 217.5K | |
Total Revenue | 1.9M | 178.1K | 171.2K | 2.0M | 3.5M | 3.6M | |
Gross Profit | 63.1K | (97.7K) | (70.8K) | 456.5K | 1.1M | 1.1M | |
Operating Income | (4.9M) | (10.2M) | (10.0M) | (12.0M) | (11.9M) | (11.3M) | |
Ebit | (4.9M) | (9.9M) | (10.1M) | (12.0M) | (12.1M) | (11.5M) | |
Ebitda | (4.9M) | (9.8M) | (9.9M) | (11.8M) | (11.8M) | (11.3M) | |
Income Before Tax | (13.6M) | (9.9M) | (10.0M) | (11.9M) | (12.3M) | (11.7M) | |
Net Income | (13.6M) | (9.9M) | (10.0M) | (11.9M) | (12.3M) | (11.7M) | |
Cost Of Revenue | 1.9M | 275.9K | 242.0K | 1.5M | 2.4M | 2.5M | |
Research Development | 2.1M | 3.9M | 4.9M | 6.9M | 5.1M | 2.9M | |
Income Tax Expense | 7.5M | 274.2K | (109.9K) | 31.4K | 36.1K | 34.3K |
Neuroone Medical Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | 3.8M | 2.9M | 1.3M | (2.8M) | (3.9M) | (3.7M) | |
Free Cash Flow | (3.5M) | (8.7M) | (7.8M) | (13.3M) | (11.1M) | (10.6M) | |
Other Non Cash Items | 6.7M | 69.4K | 212.2K | 96.4K | (285.0K) | (270.7K) | |
Capital Expenditures | 122.4K | 67.1K | 275.2K | 384.1K | 120.2K | 91.7K | |
End Period Cash Flow | 4.0M | 6.9M | 8.2M | 5.3M | 1.5M | 1.8M | |
Net Income | (13.6M) | (9.9M) | (10.0M) | (11.9M) | (12.3M) | (11.7M) | |
Investments | (122.4K) | (67.1K) | (3.2M) | 2.6M | (120.2K) | (126.2K) | |
Depreciation | 47.6K | 80.7K | 118.6K | 199.3K | 246.8K | 259.1K | |
Change To Netincome | 1.2M | 8.7M | 1.8M | 1.1M | 1.3M | 2.2M |
Neuroone Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Neuroone Medical's current stock value. Our valuation model uses many indicators to compare Neuroone Medical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neuroone Medical competition to find correlations between indicators driving Neuroone Medical's intrinsic value. More Info.Neuroone Medical Technologies is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Neuroone Medical's Return On Equity is projected to drop based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Neuroone Medical's earnings, one of the primary drivers of an investment's value.Neuroone Medical Tec Systematic Risk
Neuroone Medical's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Neuroone Medical volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Neuroone Medical Tec correlated with the market. If Beta is less than 0 Neuroone Medical generally moves in the opposite direction as compared to the market. If Neuroone Medical Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Neuroone Medical Tec is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Neuroone Medical is generally in the same direction as the market. If Beta > 1 Neuroone Medical moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Neuroone Medical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Neuroone Medical's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Neuroone Medical growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Neuroone Medical December 21, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Neuroone Medical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Neuroone Medical Technologies. We use our internally-developed statistical techniques to arrive at the intrinsic value of Neuroone Medical Technologies based on widely used predictive technical indicators. In general, we focus on analyzing Neuroone Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Neuroone Medical's daily price indicators and compare them against related drivers.
Information Ratio | (0.04) | |||
Maximum Drawdown | 28.93 | |||
Value At Risk | (9.52) | |||
Potential Upside | 10.61 |
Complementary Tools for Neuroone Stock analysis
When running Neuroone Medical's price analysis, check to measure Neuroone Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuroone Medical is operating at the current time. Most of Neuroone Medical's value examination focuses on studying past and present price action to predict the probability of Neuroone Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuroone Medical's price. Additionally, you may evaluate how the addition of Neuroone Medical to your portfolios can decrease your overall portfolio volatility.
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Stocks Directory Find actively traded stocks across global markets | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |